Absci (ABSI) Set to Announce Earnings on Thursday

Absci (NASDAQ:ABSI) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.1889) per share and revenue of $0.63 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Absci (NASDAQ:ABSI) last posted its earnings results on Tuesday, August 11th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.92 million. Absci had a negative net margin of 7,756.38% and a negative return on equity of 61.71%. On average, analysts expect Absci to post ($0.76) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

Absci Trading Up 6.2%

Shares of NASDAQ:ABSI opened at $10.80 on Tuesday. The company has a 50 day moving average of $9.61 and a 200-day moving average of $6.68. The firm has a market cap of $1.85 billion, a P/E ratio of -13.50 and a beta of 2.22. Absci has a twelve month low of $2.24 and a twelve month high of $12.54.

Wall Street Analysts Forecast Growth

ABSI has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a research note on Thursday, October 15th. JPMorgan Chase & Co. upped their target price on Absci from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Lifesci Capital began coverage on Absci in a research note on Wednesday, September 9th. They set an “outperform” rating for the company. KeyCorp lifted their price target on Absci from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Finally, Jefferies Financial Group began coverage on Absci in a research report on Thursday, October 29th. They set a “buy” rating and a $14.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.50.

About Absci

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines.

The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

Founded in 2011 by Sean McClain, Absci is headquartered in Vancouver, Washington.